McAfee Melinda R. sold $238K of VSXY

Victoria's Secret (VSXY) stock rose 5.1% after analysts raised price targets and issued positive ratings. Barclays, Morgan Stanley, and Needham analysts cited strong demand, momentum, and a multi-year turnaround. The company's shares have been volatile, with a 79.3% gain YTD. Q3 results beat estimates, with revenue of $1.47B and same-store sales up 8%.

AstraZeneca (AZN) shares rose 1.8% premarket after Oracle (ORCL) announced a non-binding AI collaboration. Victoria’s Secret (VSXY) gained 1% following a Barclays price target increase to $112. EyePoint Pharmaceuticals (EYPT) fell 4.4% after JPMorgan downgraded it to 'Underweight' due to a clinical trial setback.

Victoria’s Secret revived its iconic Angels, Fantasy Bra, and glamorous imagery at its 2026 fashion show, marking a shift from its 2021 rebranding. The company reported $1.611B in Q2 net sales, up 10% YoY, and raised its full-year sales forecast. Analyst Simeon Siegel notes the brand's challenge is restoring cultural relevance, which could support pricing power and business health.

Victoria’s Secret (VSXY) announced Chief Legal Officer Melinda McAfee will depart by March 31, 2027. She will stay in her role until a successor is appointed, then serve in a non-executive role until her departure. The company will provide severance benefits under a transition agreement.

Victoria's Secret & Co. reported Q2 2026 net sales up 10% and adjusted EPS nearly tripled, raising full-year guidance for sales, operating income, and EPS. The company's Path to Potential plan showed five quarters of positive comparable sales, driven by international demand and new customer acquisition. Analysts debate the sustainability of this momentum and the impact of store exposure, tariffs, and debt. The stock's valuation and future earnings growth are key focus areas.

Victorias Secret & Co. (VSXY) reported Q2 2026 net sales up 10% to $1.611B, adjusted EPS nearly tripled to $0.95, and raised full-year guidance. Analysts are divided: Morgan Stanley, Barclays, and JPMorgan see the turnaround continuing, while BMO and UBS believe the stock already reflects recovery. Hedge funds adjusted stakes, with Arrowstreet Capital increasing its position by 47%.